Sangamo Therapeutics (SGMOQ) Liabilities and Shareholders Equity (2010 - 2025)

Sangamo Therapeutics' Liabilities and Shareholders Equity history runs 16 years deep, the most recent figure standing at $59.7 million for Q4 2025.

• On a quarterly basis, Liabilities and Shareholders Equity fell 41.22% year-over-year to $59.7 million in Q4 2025; TTM through Dec 2025 was $332.1 million, a 23.63% decrease from a year earlier, with the FY2025 full-year figure at $59.7 million, down 41.22% from the prior year.
• Liabilities and Shareholders Equity fell to $59.7 million in Q4 2025 per SGMOQ's latest filing, from $88.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $877.1 million in Q1 2021 and bottomed at $59.7 million in Q4 2025.
• The 5-year median for Liabilities and Shareholders Equity is $272.4 million (2023), against an average of $377.6 million.
• Across the five-year window, Liabilities and Shareholders Equity jumped 50.12% in 2021 and sank 71.39% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $721.9 million in 2021, then retreated by 22.08% to $562.5 million in 2022, then slumped by 70.61% to $165.3 million in 2023, then slumped by 38.52% to $101.6 million in 2024, then sank by 41.22% to $59.7 million in 2025.
• Per Business Quant, the three latest SGMOQ Liabilities and Shareholders Equity figures stand at $59.7 million (Q4 2025), $88.6 million (Q3 2025), and $97.6 million (Q2 2025).